Tony Traboulsee
Research Classification
Research Interests
Relevant Thesis-Based Degree Programs
Affiliations to Research Centres, Institutes & Clusters
Research Options
Research Methodology
Recruitment
Image analysis related:
- Brain and spinal cord MRI image analysis of conventional and advanced MRI sequences related to multiple sclerosis
- Involvement in multicentre repository of advanced MRI data for machine learning and other applications
Clinical sciences in multiple sclerosis and rare diseases (NMOSD, MOGAD)
- clinical and MRI studies on progression and remyelination in MS>
- characterizing NMOSD and MOGAD in BC
Image analysis development related projects:
- Physics, math, computing science, electrical engineering, stats background preferred
Clinical sciences projects
- neuroscience, epidemiology, health sciences background preferred
Complete these steps before you reach out to a faculty member!
- Familiarize yourself with program requirements. You want to learn as much as possible from the information available to you before you reach out to a faculty member. Be sure to visit the graduate degree program listing and program-specific websites.
- Check whether the program requires you to seek commitment from a supervisor prior to submitting an application. For some programs this is an essential step while others match successful applicants with faculty members within the first year of study. This is either indicated in the program profile under "Admission Information & Requirements" - "Prepare Application" - "Supervision" or on the program website.
- Identify specific faculty members who are conducting research in your specific area of interest.
- Establish that your research interests align with the faculty member’s research interests.
- Read up on the faculty members in the program and the research being conducted in the department.
- Familiarize yourself with their work, read their recent publications and past theses/dissertations that they supervised. Be certain that their research is indeed what you are hoping to study.
- Compose an error-free and grammatically correct email addressed to your specifically targeted faculty member, and remember to use their correct titles.
- Do not send non-specific, mass emails to everyone in the department hoping for a match.
- Address the faculty members by name. Your contact should be genuine rather than generic.
- Include a brief outline of your academic background, why you are interested in working with the faculty member, and what experience you could bring to the department. The supervision enquiry form guides you with targeted questions. Ensure to craft compelling answers to these questions.
- Highlight your achievements and why you are a top student. Faculty members receive dozens of requests from prospective students and you may have less than 30 seconds to pique someone’s interest.
- Demonstrate that you are familiar with their research:
- Convey the specific ways you are a good fit for the program.
- Convey the specific ways the program/lab/faculty member is a good fit for the research you are interested in/already conducting.
- Be enthusiastic, but don’t overdo it.
G+PS regularly provides virtual sessions that focus on admission requirements and procedures and tips how to improve your application.
ADVICE AND INSIGHTS FROM UBC FACULTY ON REACHING OUT TO SUPERVISORS
These videos contain some general advice from faculty across UBC on finding and reaching out to a potential thesis supervisor.
Supervision Enquiry
Great Supervisor Week Mentions
I offer my heartfelt thanks to Drs. Shannon Kolind and Anthony Traboulsee, who have taught me more than I could ever have learned in a classroom. They have provided me with unconditional support and care, and encouraged critical thinking and professional growth. Even with their busy schedules, they regularly met with me to ensure that I was meeting my goals and had all necessary resources. I am very grateful for their mentorship, trust and guidance! #GreatSupervisor week at #UBC.
Graduate Student Supervision
Doctoral Student Supervision
Dissertations completed in 2010 or later are listed below. Please note that there is a 6-12 month delay to add the latest dissertations.
The translation of novel brain technologies from the bench to the bedside has been characterized by a tension between priorities to promote rapid access to experimental interventions and the utilitarian pursuit of their evaluation with rigorous and time-intensive research. Through three studies conducted within the scope of this dissertation, I focus on a central research question: What are the perspectives of stakeholders about the translation of novel biotechnologies for neurodegenerative disease?Harnessing the strength of pragmatic neuroethics, I address this research question using both qualitative and quantitative analyses. In the first study, I explore the perspectives of patients with multiple sclerosis (MS) about the unproven but highly publicized chronic cerebrospinal venous insufficiency (CCSVI) intervention and the impact of its controversial trajectory on stem cell research. I find that patients are disappointed about the divestment of funds from other areas of research to support CCSVI trials, but maintain enduring hopes for future neurotechnological advancements, including stem cell research. In the second study, I examine how the news media represent timeframes for research and development of stem cell interventions for MS and other neurodegenerative diseases. I find that news articles celebrate the benefits of stem cell research with little context of its caveats. In contrast to prior studies, however, I discover that they also conscientiously convey caution about stem cell tourism and describe a lengthy trajectory between research and clinical availability of therapeutics. In the third study, I explore the perspectives of patients with MS and clinicians responsible for their care about the pace of research and development for stem cell interventions. Here I describe the urgency that patients feel to access stem cell interventions and their desire to learn more about the research process. Clinicians suggest strategies for dialogue with their patients that can clarify translational timeframes and inform hopes. Overall, the findings bring together the voices of key stakeholders and support a commitment to socially minded translation of novel neurotechnologies for neurodegenerative disease.
View record
Master's Student Supervision
Theses completed in 2010 or later are listed below. Please note that there is a 6-12 month delay to add the latest theses.
Neuromyelitis optica (NMO) and multiple sclerosis (MS) both result in acute injury (i.e. attacks or relapses) to the central nervous system with focal demyelination and axonal loss that varies in severity along a spectrum. A variety of non-invasive structural imaging and functional tools can be used to investigate mechanisms of white matter injury and secondary axonal injury in MS and NMO. These include advanced magnetic resonance imaging (MRI) measures of myelin water fraction; optical coherence tomography (OCT) for retinal nerve fibre layer thickness and total macular volume; and transcranial magnetic stimulation (TMS) to determine cortical excitability and integrity of cortical spinal pathways.First, the relationship between a functional measure using TMS and a structural measure of myelin in the cortico-spinal tract was examined. Structural changes were found in the descending motor output pathway white matter in NMO along with abnormal TMS measures, suggesting that there is greater spinal cord involvement and more extensive axonal loss found in NMO compared to MS.Next, OCT was used as a measure of the anterior visual pathway and myelin water imaging of the posterior visual pathway; the effects of damage to one part of the visual system on the other was studied. Retrograde degeneration to the retina and anterograde degeneration to the optic radiations from the optic nerve was observed in both MS and NMO subjects with optic neuritis history. A correlation between the measures indicating that damage to one part may cause damage to another part of the visual pathway. Finally, damage was observed in optic pathway in MS patients without optic neuritis history suggesting that there is damage in the absence of lesions in the optic nerve.Finally, myelin water imaging was used to investigate if the disease burden of lesions regulate the level of damage to the normal appearing white matter (NAWM) tracts. The lack of correlation between disease burden of lesions and NAWM myelin water imaging in MS suggested that damage to the NAWM was mediated by processes independent of lesions.These techniques can be used to study and better understand demyelinating diseases such as MS and NMO.
View record
Magnetic Resonance Imaging (MRI) measures of T₁ relaxation provide a sensitive and reproducible measure of water content in vivo. In the present study T₁ histograms were used to monitor changes in the brain water content of multiple sclerosis (MS) patients initiating Disease Modifying Therapies (DMT). The initiation of DMT, which target inflammation, is associated with a decrease in brain volume (BV) greater than would be expected by natural history alone. Reductions in BV may reflect worsening disease in untreated patients; however for patients treated with DMT, reductions in BV early in the treatment course may represent a clinical improvement due to initial anti-inflammatory effects of therapy and the resulting decrease in edema. The initial change in BV upon starting DMT is termed pseudoatrophy, a reversible decrease in BV due to a loss of water from the brain parenchyma. Patients with clinically definite MS planning on initiating DMT were recruited and scanned at two time points prior to initiating therapy and two time points after initiating therapy to determine the change in water content of the brain.
View record
Publications
- Accounting for uncertainty in training data to improve machine learning performance in predicting new disease activity in early multiple sclerosis (2023)
Frontiers in Neurology, 14 - Cancer risk, disease-modifying therapy, and age in multiple sclerosis: A retrospective population-based cohort study (2023)
Multiple Sclerosis and Related Disorders, 80 - Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study in British Columbia, Canada, 2001-2020 (2023)
Neurology, 100 (9), E899-E910 - Employment status, productivity loss, and associated factors among people with multiple sclerosis (2023)
Multiple Sclerosis Journal, 29 (7), 866-874 - Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar (2023)
Neurology: Neuroimmunology and NeuroInflammation, 10 (1) - Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results (2023)
Multiple Sclerosis and Related Disorders, 73 - Myelin heterogeneity for assessing normal appearing white matter myelin damage in multiple sclerosis (2023)
Journal of Neuroimaging, 33 (2), 227-234 - Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension (2023)
Journal of Neurology - Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging (2023)
Multiple Sclerosis Journal, 29 (6), 741-747 - Safety of Tocilizumab in the treatment of COVID-19 related longitudinally extensive transverse myelitis (2023)
Canadian Journal of Neurological Sciences - SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab (2023)
Frontiers in Neurology, 14 - A pilot study comparing myelin measurements from myelin water imaging and 11C-PIB PET in multiple sclerosis (2022)
Multiple Sclerosis and Related Disorders, 68 - Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data (2022)
Multiple Sclerosis Journal, 28 (5), 842-846 - Cervical Spinal Cord Atrophy can be Accurately Quantified Using Head Images (2022)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 8 (1) - Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging (2022)
Multiple Sclerosis Journal, 28 (3), 418-428 - Cortical morphology predicts placebo response in multiple sclerosis (2022)
Scientific Reports, 12 (1) - Diffusely abnormal white matter in clinically isolated syndrome is associated with parenchymal loss and elevated neurofilament levels (2022)
Multiple Sclerosis and Related Disorders, 57 - Diffusely abnormal white matter in multiple sclerosis (2022)
Journal of Neuroimaging, 32 (1), 5-16 - Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels (2022)
Multiple Sclerosis Journal, 28 (13), 2081-2089 - Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a (2022)
NeuroImage: Clinical, 35 - Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS (2022)
Multiple Sclerosis Journal, 28 (12), 1927-1936 - Productivity loss among people with early multiple sclerosis: A Canadian study (2022)
Multiple Sclerosis Journal, 28 (9), 1414-1423 - Quantitative MRI findings indicate diffuse white matter damage in Susac Syndrome (2022)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 8 (1) - Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis (2022)
Multiple Sclerosis and Related Disorders, 57 - The reality of multiple sclerosis assessment in middle-income countries – Authors' reply (2022)
The Lancet Neurology, 21 (3), 215-216 - 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (2021)
The Lancet Neurology, 20 (8), 653-670 - An atlas for human brain myelin content throughout the adult life span (2021)
Scientific Reports, 11 (1) - Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis (2021)
Multiple Sclerosis Journal, 27 (14), 2191-2198 - Comparison of multi echo T2 relaxation and steady state approaches for myelin imaging in the central nervous system (2021)
Scientific Reports, 11 (1) - Corpus callosum lesions are not inextricably linked to CNS symptoms in reported cases of susac syndrome (2021)
Multiple Sclerosis and Related Disorders, 51 - Diagnosis of Progressive Multiple Sclerosis from the Imaging Perspective: A Review (2021)
JAMA Neurology, 78 (3), 351-364 - Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial (2021)
Therapeutic Advances in Neurological Disorders, 14 - Elevated levels of serum CD5 antigen-like protein distinguish secondary progressive multiple sclerosis from other disease subtypes (2021)
Multiple Sclerosis and Related Disorders, 56 - Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosis (2021)
Multiple Sclerosis and Related Disorders, 50 - Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort (2021)
Frontiers in Neurology, 11 - Myelin-oligodendrocyte glycoprotein antibody-associated disease (2021)
The Lancet Neurology, 20 (9), 762-772 - Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis (2021)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 7 (3) - Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial (2021)
The Lancet Neurology, 20 (9), 729-738 - The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design (2021)
BMC Neurology, 21 (1) - Water content changes in new multiple sclerosis lesions have a minimal effect on the determination of myelin water fraction values (2021)
Journal of Neuroimaging, 31 (6), 1119-1125 - An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis (2020)
International Journal of MS Care, 22 (5), 226-232 - Associations between Findings from Myelin Water Imaging and Cognitive Performance among Individuals with Multiple Sclerosis (2020)
JAMA Network Open, 3 (9), E2014220 - Both Stationary and Dynamic Functional Interhemispheric Connectivity Are Strongly Associated With Performance on Cognitive Tests in Multiple Sclerosis (2020)
Frontiers in Neurology, 11 - Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study (2020)
Neurology, 95 (14), E1999-E2008 - Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study (2020)
CNS Drugs, 34 (9), 973-988 - Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies (2020)
Multiple Sclerosis Journal, 26 (14), 1866-1876 - Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension (2020)
Neurology, 95 (13), E1854-E1867 - Genetic analysis of nucleotide-binding leucine-rich repeat (NLR) receptors in multiple sclerosis (2020)
Immunogenetics, 72 (6-7), 381-385 - Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223 (2020)
Journal of Neurology, 267 (11), 3343-3353 - Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients (2020)
Journal of Neuro-Ophthalmology, 40 (1), 37-43 - Myelin Damage in Normal Appearing White Matter Contributes to Impaired Cognitive Processing Speed in Multiple Sclerosis (2020)
Journal of Neuroimaging, 30 (2), 205-211 - Myelin Water Fraction and Intra/Extracellular Water Geometric Mean T2 Normative Atlases for the Cervical Spinal Cord from 3T MRI (2020)
Journal of Neuroimaging, 30 (1), 50-57 - Myelin water imaging data analysis in less than one minute (2020)
NeuroImage, 210 - Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis (2020)
Journal of Neuroinflammation, 17 (1) - Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial (2020)
The Lancet Neurology, 19 (5), 402-412 - Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic (2020)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 6 (2) - Treatment of MOG antibody associated disorders: results of an international survey (2020)
Journal of Neurology, 267 (12), 3565-3577 - A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab (2019)
Multiple Sclerosis Journal, 25 (6), 811-818 - Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease? (2019)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 5 (1) - Analysis of galanin receptor GALR2 in multiple sclerosis (2019)
Pharmacogenomics Journal, 19 (6), 499-500 - Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines (2019)
Brain, 142 (7), 1858-1875 - Association of unemployment and informal care with stigma in multiple sclerosis: Evidence from the survey on living with neurological conditions in Canada (2019)
International Journal of MS Care, 21 (5), 215-225 - Author response: Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial (2019)
Neurology, 93 (7), 320 - Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings (2019)
Frontiers in Neurology, 10 - Cannabis-based product use in a multiple sclerosis cohort (2019)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 5 (3) - Case of alemtuzumab-related alopecia areata management in MS (2019)
Neurology: Neuroimmunology and NeuroInflammation, 6 (1) - Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD (2019)
Neurology: Neuroimmunology and NeuroInflammation, 6 (5) - Data fusion detects consistent relations between non-lesional white matter myelin, executive function, and clinical characteristics in multiple sclerosis (2019)
NeuroImage: Clinical, 24 - Deep learning of brain lesion patterns and user-defined clinical and MRI features for predicting conversion to multiple sclerosis from clinically isolated syndrome (2019)
Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 7 (3), 250-259 - Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients (2019)
BMC Neurology, 19 (1) - Diffusely Abnormal White Matter, T 2 Burden of Disease, and Brain Volume in Relapsing-Remitting Multiple Sclerosis (2019)
Journal of Neuroimaging, 29 (1), 151-159 - Effect of different doses of gadolinium contrast agent on clinical outcomes in MS (2019)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 5 (1) - Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease (2019)
PLoS Genetics, 15 (6) - FLAIR2 improves LesionTOADS automatic segmentation of multiple sclerosis lesions in non-homogenized, multi-center, 2D clinical magnetic resonance images (2019)
NeuroImage: Clinical, 23 - Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS (2019)
Neurology, 92 (11), 519-533 - Increased mean R2* in the deep gray matter of multiple sclerosis patients: Have we been measuring atrophy? (2019)
Journal of Magnetic Resonance Imaging, 50 (1), 201-208 - Intra- and inter-site reproducibility of human brain single-voxel proton MRS at 3 T (2019)
NMR in Biomedicine, 32 (6) - Laboratory Monitoring Practices Among Canadian Multiple Sclerosis Clinicians (2019)
Canadian Journal of Neurological Sciences, 46 (4), 389-393 - Longitudinal advanced MRI case report of white matter radiation necrosis (2019)
Annals of Clinical and Translational Neurology, 6 (2), 379-385 - Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression (2019)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 5 (4) - Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a (2019)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 5 (4) - Multicenter Measurements of T 1 Relaxation and Diffusion Tensor Imaging: Intra and Intersite Reproducibility (2019)
Journal of Neuroimaging, 29 (1), 42-51 - Myelin Water Atlas: A Template for Myelin Distribution in the Brain (2019)
Journal of Neuroimaging, 29 (6), 699-706 - Myelin Water Imaging and Transcranial Magnetic Stimulation Suggest Structure-Function Relationships in Multiple Sclerosis (2019)
Frontiers in Physics, 7 - Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies (2019)
Multiple Sclerosis and Related Disorders, 30, 236-243 - Perspectives about time frames in stem cell research for multiple sclerosis "Time Is Brain" (2019)
International Journal of MS Care, 21 (4), 185-193 - Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b (2019)
Multiple Sclerosis Journal, 25 (6), 837-847 - Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis (2019)
Human Brain Mapping, 40 (7), 2104-2116 - Rapid myelin water imaging for the assessment of cervical spinal cord myelin damage (2019)
NeuroImage: Clinical, 23 - Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (2019)
The Lancet Neurology, 18 (2), 185-197 - Three-dimensional MRI sequences in MS diagnosis and research (2019)
Multiple Sclerosis Journal, 25 (13), 1700-1709 - Analysis of NOD-like receptor NLRP1 in multiple sclerosis families (2018)
Immunogenetics, 70 (3), 205-207 - Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis (2018)
Nature Genetics, 50 (8), 1081-1085 - Deep learning of joint myelin and T1w MRI features in normal-appearing brain tissue to distinguish between multiple sclerosis patients and healthy controls (2018)
NeuroImage: Clinical, 17, 169-178 - Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018)
The Lancet Neurology, 17 (2), 162-173 - Education, and the balance between dynamic and stationary functional connectivity jointly support executive functions in relapsing–remitting multiple sclerosis (2018)
Human Brain Mapping, 39 (12), 5039-5049 - Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1 (2018)
BMC Neurology, 18 (1) - Gadolinium deposition in deep brain structures: Relationship with dose and ionization of linear gadolinium-based contrast agents (2018)
American Journal of Neuroradiology, 39 (9), 1597-1603 - Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter (2018)
Multiple Sclerosis Journal, 24 (12), 1557-1568 - Goodpasture's Syndrome Following Alemtuzumab Therapy in Multiple Sclerosis (2018)
Canadian Journal of Neurological Sciences, 45 (6), 712-714 - Inter-vendor reproducibility of myelin water imaging using a 3D gradient and spin echo sequence (2018)
Frontiers in Neuroscience, 12 (NOV) - No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a (2018)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 4 (1), 1-11 - Nothing Ventured, Nothing Gained? Navigating Disease-Modifying Treatment in Multiple Sclerosis (2018)
Canadian Journal of Neurological Sciences, 45 (5), 487-488 - Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation (2018)
Multiple Sclerosis and Related Disorders, 20, 37-42 - Perspectives of patients with multiple sclerosis on drug treatment: A qualitative study (2018)
International Journal of MS Care, 20 (6), 269-277 - Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: An exploratory analysis of the PRISMS study (2018)
BMC Neurology, 18 (1) - Reflections on translation: Views of participants in a multisiteCanadianCCSVI clinical trial (2018)
Neurology: Clinical Practice, 8 (3), 232-239 - Resilience, trust, and civic engagement in the post-CCSVI era (2018)
BMC Health Services Research, 18 (1) - Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial (2018)
Neurology, 91 (18), E1660-E1668 - What have we learned from perfusion MRI in multiple sclerosis? (2018)
American Journal of Neuroradiology, 39 (6), 994-1000 - Alemtuzumab CARE-MS i 5-year follow-up: Durable efficacy in the absence of continuous MS therapy (2017)
Neurology, 89 (11), 1107-1116 - Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings (2017)
Neurology, 89 (11), 1117-1126 - Anisotropic cerebral vascular architecture causes orientation dependency in cerebral blood flow and volume measured with dynamic susceptibility contrast magnetic resonance imaging (2017)
Journal of Cerebral Blood Flow and Metabolism, 37 (3), 1108-1119 - Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: A case-control study protocol for dimethyl fumarate-induced lymphopenia (2017)
BMJ Open, 7 (5) - At the crossroads of civic engagement and evidence-based medicine: Lessons learned from the chronic cerebrospinal venous insufficiency experience (2017)
Neuroethics: Anticipating the Future, 264-273 - Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder (2017)
NeuroImage: Clinical, 16, 17-22 - Characterization of brain tumours with spin–spin relaxation: pilot case study reveals unique T 2 distribution profiles of glioblastoma, oligodendroglioma and meningioma (2017)
Journal of Neurology, 264 (11), 2205-2214 - Cognitive performance in subjects with multiple sclerosis is robustly influenced by gender in canonical-correlation analysis (2017)
Journal of Neuropsychiatry and Clinical Neurosciences, 29 (2), 119-127 - Common genetic etiology between “multiple sclerosis-like” single-gene disorders and familial multiple sclerosis (2017)
Human Genetics, 136 (6), 705-714 - Evaluating the safety of β-interferons in MS (2017)
Neurology, 88 (24), 2310-2320 - Genetic modifiers of multiple sclerosis progression, severity and onset (2017)
Clinical Immunology, 180, 100-105 - Grey matter segmentation in spinal cord mris via 3D convolutional encoder networks with shortcut connections (2017)
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 10553 LNCS, 330-337 - Hierarchical multimodal fusion of deep-learned lesion and tissue integrity features in brain MRIs for distinguishing neuromyelitis optica from multiple sclerosis (2017)
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 10435 LNCS, 480-488 - Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis (2017)
New England Journal of Medicine, 376 (3), 221-234 - Ocrelizumab versus placebo in primary progressive multiple sclerosis (2017)
New England Journal of Medicine, 376 (3), 209-220 - Patient-Reported Benefits of Extracranial Venous Therapy: British Columbia CCSVI Registry (2017)
Canadian Journal of Neurological Sciences, 44 (3), 246-254 - Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: “Second International Workshop on Human Endogenous Retroviruses and Disease”, Washington DC, March 13th and 14th 2017 (2017)
Multiple Sclerosis and Related Disorders, 15, 18-23 - Prevalence of Extracranial Venous Narrowing on Magnetic Resonance Venography Is Similar in People With Multiple Sclerosis, Their Siblings, and Unrelated Healthy Controls: A Blinded, Case-Control Study (2017)
Canadian Association of Radiologists Journal, 68 (2), 202-209 - Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis (2017)
Human Mutation, 38 (6), 736-744 - Rapid myelin water imaging in human cervical spinal cord (2017)
Magnetic Resonance in Medicine, 78 (4), 1482-1487 - Sodium intake and multiple sclerosis activity and progression in BENEFIT (2017)
Annals of Neurology, 82 (1), 20-29 - Subcutaneous interferon b-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials (2017)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 3 (4), 1-11 - Susceptibility-sensitive MRI of multiple sclerosis lesions and the impact of normal-appearing white matter changes (2017)
NMR in Biomedicine, 30 (8) - Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review (2017)
Autoimmunity Reviews, 16 (6), 658-665 - Trial of minocycline in a clinically isolated syndrome of multiple sclerosis (2017)
New England Journal of Medicine, 376 (22), 2122-2133 - Addressing concerns regarding the use of gadolinium in a standardized mri protocol for the diagnosis and follow-up of multiple sclerosis (2016)
American Journal of Neuroradiology, 37 (12), E82-E83 - Analysis of CH25H in multiple sclerosis and neuromyelitis optica (2016)
Journal of Neuroimmunology, 291, 70-72 - Analysis of plasminogen genetic variants in multiple sclerosis patients (2016)
G3: Genes, Genomes, Genetics, 6 (7), 2073-2079 - Brain health: time matters in multiple sclerosis (2016)
Multiple Sclerosis and Related Disorders, 9, S5-S48 - Case-Control Studies Are Not Familial Studies (2016)
Neuron, 92 (2), 339-341 - Characterizing pediatric-onset neuromyelitis optica spectrum disorder in british Columbia (2016)
British Columbia Medical Journal, 58 (1), 25-29 - Corpus callosum segmentation in brain MRIs via robust target-localization and joint supervised feature extraction and prediction (2016)
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 9901 LNCS, 406-414 - Corticospinal tract integrity measured using transcranial magnetic stimulation and magnetic resonance imaging in neuromyelitis optica and multiple sclerosis (2016)
Multiple Sclerosis, 22 (1), 43-50 - Deep 3D Convolutional Encoder Networks With Shortcuts for Multiscale Feature Integration Applied to Multiple Sclerosis Lesion Segmentation (2016)
IEEE Transactions on Medical Imaging, 35 (5), 1229-1239 - Deep learning of brain lesion patterns for predicting future disease activity in patients with early symptoms of multiple sclerosis (2016)
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 10008 LNCS, 86-94 - Does hydration status affect MRI measures of brain volume or water content? (2016)
Journal of Magnetic Resonance Imaging, 44 (2), 296-304 - Editorial Note to:Nuclear Receptor NR1H3 in Familial Multiple Sclerosis (2016)
Neuron, 92 (2), 331-332 - Erratum: Nuclear Receptor NR1H3 in Familial Multiple Sclerosis (Neuron (2016) 90(5) (948–954)(S089662731630126X)(10.1016/j.neuron.2016.04.039)) (2016)
Neuron, 92 (2), 555 - FLAIR2: A combination of FLAIR and T2 for improved MS lesion detection (2016)
American Journal of Neuroradiology, 37 (2), 259-265 - Longitudinal study of retinal nerve fiber layer thickness and macular volume in patients with neuromyelitis optica spectrum disorder (2016)
Journal of Neuro-Ophthalmology, 36 (4), 363-368 - Multiple measures of corticospinal excitability are associated with clinical features of multiple sclerosis (2016)
Behavioural Brain Research, 297, 187-195 - Nuclear Receptor NR1H3 in Familial Multiple Sclerosis (2016)
Neuron, 90 (5), 948-954 - Prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis (2016)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2 - Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years (2016)
Multiple Sclerosis, 22 (1), 112-116 - Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica (2016)
NeuroImage: Clinical, 11, 743-750 - Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: A best-worst scaling study (2016)
Therapeutic Advances in Neurological Disorders, 9 (4), 287-296 - Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis (2016)
American Journal of Neuroradiology, 37 (3), 394-401 - A sensitive and efficient method for measuring change in cortical thickness using fuzzy correspondence in Alzheimer's disease (2015)
Proceedings - International Conference on Image Processing, ICIP, 2015-December, 3014-3018 - An Assessment of Genetic Counseling Services for Individuals with Multiple Sclerosis (2015)
Journal of Genetic Counseling, 24 (1), 46-57 - Brain and cord myelin water imaging: A progressive multiple sclerosis biomarker (2015)
NeuroImage: Clinical, 9, 574-580 - Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring (2015)
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 42 (3), 159-167 - Corpus callosum segmentation in MS studies using normal atlases and optimal hybridization of extrinsic and intrinsic image cues (2015)
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 9351, 123-131 - Deep convolutional encoder networks for multiple sclerosis lesion segmentation (2015)
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 9351, 3-11 - Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations (2015)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 1 - Fast computation of myelin maps from MRI T2 relaxation data using multicore CPU and graphics card parallelization (2015)
Journal of Magnetic Resonance Imaging, 41 (3), 700-707 - Further investigation of safety monitoring guidelines based on magnetic resonance imaging lesion activity in multiple sclerosis clinical trials (2015)
Multiple Sclerosis Journal, 21 (1), 101-104 - Health-related quality of life in patients with longstanding 'benign multiple sclerosis' (2015)
Multiple Sclerosis and Related Disorders, 4 (1), 31-38 - Imaging surrogates of disease activity in neuromyelitis optica allow distinction from multiple sclerosis (2015)
PLoS ONE, 10 (9) - Incidence of Multiple Sclerosis and Related Disorders in Asian Populations of British Columbia (2015)
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 42 (4), 235-241 - International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (2015)
Neurology, 85 (2), 177-189 - Orientation dependent mr signal decay differentiates between people with MS, their asymptomatic siblings and unrelated healthy controls (2015)
PLoS ONE, 10 (10) - Personalized activity index, a new safety monitoring tool for multiple sclerosis clinical trials (2015)
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 1 - Analysis of CYP27B1 in multiple sclerosis (2014)
Journal of Neuroimmunology, 266 (1-2), 64-66 - Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes (2014)
Multiple Sclerosis Journal, 20 (4), 458-463 - Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs (2014)
CNS Drugs, 28 (5), 475-482 - Birth outcomes of pregnancies fathered by men with multiple sclerosis (2014)
Multiple Sclerosis Journal, 20 (9), 1260-1264 - Deep learning of image features from unlabeled data for multiple sclerosis lesion segmentation (2014)
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 8679, 117-124 - Dehydration affects spinal cord cross-sectional area measurement on MRI in healthy subjects (2014)
Spinal Cord, 52 (8), 616-620 - Detection of unusual increases in MRI lesion counts in individual multiple sclerosis patients (2014)
Journal of the American Statistical Association, 109 (505), 119-132 - Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression (2014)
Neurogenetics, 15 (3), 165-169 - How useful are MS registries? (2014)
Multiple Sclerosis Journal, 20 (11), 1423-1424 - Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning (2014)
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 8674 LNCS (PART 2), 462-469 - Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning (2014)
Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention, 17, 462-469 - Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: A blinded, case-control study (2014)
The Lancet, 383 (9912), 138-145 - Progressive multiple sclerosis does not associate with rs996343 and rs2046748 (2014)
Multiple Sclerosis Journal, 20 (6), 766-767 - Association of smoking with risk of multiple sclerosis: A population-based study (2013)
Journal of Neurology, 260 (7), 1778-1781 - Characterising aggressive multiple sclerosis (2013)
Journal of Neurology, Neurosurgery and Psychiatry, 84 (11), 1192-1198 - Colony stimulation factor 1 receptor (CSF1R) is not a common cause of multiple sclerosis (2013)
European Journal of Neurology, 20 (9) - Diffusely abnormal white matter in multiple sclerosis: Further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration (2013)
Journal of Neuropathology and Experimental Neurology, 72 (1), 42-52 - Labor induction and augmentation in women with multiple sclerosis (2013)
Multiple Sclerosis Journal, 19 (9), 1182-1189 - Magnetic resonance frequency shifts during acute MS lesion formation (2013)
Neurology, 81 (3), 211-218 - Multicenter measurements of myelin water fraction and geometric mean T 2: Intra- and intersite reproducibility (2013)
Journal of Magnetic Resonance Imaging, 38 (6), 1445-1453 - Obstetrical epidural and spinal anesthesia in multiple sclerosis (2013)
Journal of Neurology, 260 (10), 2620-2628 - Pathological correlates of magnetic resonance imaging texture heterogeneity in multiple sclerosis (2013)
Annals of Neurology, 74 (1), 91-99 - Retinal nerve fiber layer thickness in benign multiple sclerosis (2013)
Multiple Sclerosis Journal, 19 (10), 1275-1281 - Safety of disease-modifying drugs for multiple sclerosis in pregnancy: Current challenges and future considerations for effective pharmacovigilance (2013)
Expert Review of Neurotherapeutics, 13 (3), 251-261 - Spectral-domain optical coherence tomography of retinal nerve fiber layer thickness in NMO patients (2013)
Journal of Neuro-Ophthalmology, 33 (3), 213-219 - Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient (2013)
Multiple Sclerosis and Related Disorders, 2 (1), 57-59 - Utility of the Canadian treatment optimization recommendations (TOR) in MS care (2013)
Canadian Journal of Neurological Sciences, 40 (4), 527-535 - Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population (2013)
Neuroscience Bulletin, 29 (5), 525-530 - Comparison of MERGE and axial T2-weighted fast spin-echo sequences for detection of multiple sclerosis lesions in the cervical spinal cord (2012)
American Journal of Roentgenology, 199 (1), 157-162 - Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis (2012)
NeuroImage: Clinical, 1 (1), 29-36 - Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: Safety and efficacy results up to 8.5 years (2012)
Multiple Sclerosis Journal, 18 (9), 1278-1289 - Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis (2012)
Journal of Neurology, Neurosurgery and Psychiatry, 83 (3), 282-287 - Short-term stability of T 1 and T 2 relaxation measures in multiple sclerosis normal appearing white matter (2012)
Journal of Neurology, 259 (6), 1151-1158 - Time-domain and spectral-domain optical coherence tomography of retinal nerve fiber layer in MS patients and healthy controls (2012)
Journal of Ophthalmology, 2012 - Treatment of neuromyelitis optica: Review and recommendations (2012)
Multiple Sclerosis and Related Disorders, 1 (4), 180-187 - A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS (2011)
Neurology, 77 (16), 1551-1560 - Acute disseminated encephalomyelitis following influenza vaccination (2011)
Vaccine, 29 (46), 8182-8185 - Establishing long-term efficacy in chronic disease: Use of recursive partitioning and propensity score adjustment to estimate outcome in MS (2011)
PLoS ONE, 6 (11) - Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis (2011)
Neurology, 77 (24), 2089-2096 - Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci (2011)
Annals of Neurology, 70 (6), 897-912 - Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: Exploratory analyses from the PRISMS long-term follow-up study (2011)
Therapeutic Advances in Neurological Disorders, 4 (1), 3-14 - Is the magnetization transfer ratio a marker for myelin in multiple sclerosis? (2011)
Journal of Magnetic Resonance Imaging, 33 (3), 710-718 - Pathological basis of diffusely abnormal white matter: Insights from magnetic resonance imaging and histology (2011)
Multiple Sclerosis Journal, 17 (2), 144-150 - Postvaccination Miller Fisher syndrome (2011)
Archives of Neurology, 68 (10), 1325-1327 - Postvaccination Miller Fisher syndrome (2011)
Archives of Neurology, 68 (10), 1327-1329 - Response (2011)
Journal of Magnetic Resonance Imaging, 34 (5), 1241 - Targeting progressive neuroaxonal injury: Lessons from multiple sclerosis (2011)
CNS Drugs, 25 (9), 783-799 - Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: A preliminary study (2011)
Multiple Sclerosis Journal, 17 (5), 532-540 - The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis (2011)
Multiple Sclerosis Journal, 17 (8), 949-957 - Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial (2010)
Journal of Neurology, Neurosurgery and Psychiatry, 81 (8), 907-912 - Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS (2010)
Neurology, 74 (23), 1877-1885 - Does MRI lesion activity regress in secondary progressive multiple sclerosis? (2010)
Multiple Sclerosis, 16 (4), 434-442 - Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis (2010)
Multiple Sclerosis, 16 (6), 670-677 - Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: Results of a Canadian, multicenter, double-blind, placebo-controlled trial (2009)
Multiple Sclerosis, 15 (10), 1183-1194 - Long-term follow-up of the original interferon-β1b trial in multiple sclerosis: Design and lessons from a 16-year observational study (2009)
Clinical Therapeutics, 31 (8), 1724-1736 - Longitudinal changes in myelin water fraction in two MS patients with active disease (2009)
Journal of the Neurological Sciences, 276 (1-2), 49-53 - MR Relaxation in Multiple Sclerosis (2009)
Neuroimaging Clinics of North America, 19 (1), 1-26 - Reproducibility of myelin water fraction analysis: a comparison of region of interest and voxel-based analysis methods (2009)
Magnetic Resonance Imaging, 27 (8), 1096-1103 - Complementary information from multi-exponential T2 relaxation and diffusion tensor imaging reveals differences between multiple sclerosis lesions (2008)
NeuroImage, 40 (1), 77-85 - Conventional MR Imaging (2008)
Neuroimaging Clinics of North America, 18 (4), 651-673 - Dirty-appearing white matter in multiple sclerosis: Preliminary observations of myelin phospholipid and axonal loss (2008)
Journal of Neurology, 255 (11), 1802-1811 - Escalating immunotherapy of multiple sclerosis (2008)
Therapeutic Advances in Neurological Disorders, 1 (3), 181-192 - Invariant 3D SPHARM features for characterizing fMRI activations in ROIs while minimizing effects of intersubject anatomical variability (2008)
2008 5th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, Proceedings, ISBI, 560-563 - No effect of preterm birth on the risk of multiple sclerosis: A population based study (2008)
BMC Neurology, 8 - Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: Analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study (2008)
BMC Neurology, 8 - Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis (2008)
Neurology, 70 (13 PART 2), 1092-1097 - SPHARM-based spatial fMRI characterization with intersubject anatomical variability reduction (2008)
IEEE Journal on Selected Topics in Signal Processing, 2 (6), 907-918 - Invariant SPHARM shape descriptors for complex geometry in MR region of interest analysis (2007)
Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings, 1322-1325 - Long T2 water in multiple sclerosis: What else can we learn from multi-echo T2 relaxation? (2007)
Journal of Neurology, 254 (11), 1579-1587 - Longitudinal, regional and deformation-specific corpus callosum shape analysis for multiple sclerosis (2007)
Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings, 2110-2113 - MR evidence of long T2 water in pathological white matter (2007)
Journal of Magnetic Resonance Imaging, 26 (4), 1117-1121 - MRI relapses have significant pathologic and clinical implications in multiple sclerosis (2007)
Journal of the Neurological Sciences, 256 (SUPPL. 1) - Multi-parametric MR assessment of T1 black holes in multiple sclerosis: Evidence that myelin loss is not greater in hypointense versus isointens T1 lesions (2007)
Journal of Neurology, 254 (12), 1653-1659 - Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: A Canadian multiple sclerosis clinic-based study (2007)
Multiple Sclerosis, 13 (9), 1127-1137 - Automatic MRI brain tissue segmentation using a hybrid statistical and geometric model (2006)
2006 3rd IEEE International Symposium on Biomedical Imaging: From Nano to Macro - Proceedings, 2006, 394-397 - Brain extraction using geodesic active contours (2006)
Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 6144 II - Effects of mid-sagittal plane perturbation and image interpolation on corpus callosum area calculation (2006)
Sixth IEEE International Symposium on Signal Processing and Information Technology, ISSPIT, 197-202 - Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS (2006)
Neurology, 67 (6), 944-953 - MRI brain extraction with combined expectation maximization and geodesic active contours (2006)
Sixth IEEE International Symposium on Signal Processing and Information Technology, ISSPIT, 107-111 - Myelin water imaging in multiple sclerosis: Quantitative correlations with histopathology (2006)
Multiple Sclerosis, 12 (6), 747-753 - Optimal filter design for multiple sclerosis lesions segmentation from regions of interest in brain MRI (2006)
Sixth IEEE International Symposium on Signal Processing and Information Technology, ISSPIT, 1-5 - Semi-automated segmentation of multiple sclerosis lesions in brain MRI using texture analysis (2006)
Sixth IEEE International Symposium on Signal Processing and Information Technology, ISSPIT, 6-10 - Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines (2006)
American Journal of Neuroradiology, 27 (2), 455-461 - The role of MRI in the diagnosis of multiple sclerosis. (2006)
Advances in neurology, 98, 125-146 - The use of MRI as an outcome measure in clinical trials. (2006)
Advances in neurology, 98, 203-226 - Neuroimaging in multiple sclerosis (2005)
Neurologic Clinics, 23 (1), 131-148 - MRI: Role in optimising treatment (2004)
Journal of Neurology, Supplement, 251 (5) - Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities (2003)
Multiple Sclerosis, 9 (6), 566-573 - Interferons in relapsing remitting multiple sclerosis [1] (multiple letters) (2003)
Lancet, 361 (9371), 1821-1825 - Interferons in relapsing remitting multiple sclerosis. (2003)
Lancet, 361 (9371) - Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS (2002)
Neurology, 59 (1), 126-128
If this is your researcher profile you can log in to the Faculty & Staff portal to update your details and provide recruitment preferences.